Abstract
Although children and adolescents with acute lymphoblastic leukaemia (ALL) have high survival rates, approximately 15-20% of patients relapse. Risk of relapse is routinely estimated at diagnosis by biological factors, including flow cytometry data. This high-dimensional data is typically manually assessed by projecting it onto a subset of biomarkers. Cell density and “empty spaces” in 2D projections of the data, i.e. regions devoid of cells, are then used for qualitative assessment. Here, we use topological data analysis (TDA), which quantifies shapes, including empty spaces, in data, to analyse pre-treatment ALL datasets with known patient outcomes. We combine these fully unsupervised analyses with Machine Learning (ML) to identify significant shape characteristics and demonstrate that they accurately predict risk of relapse, particularly for patients previously classified as ‘low risk’. We independently confirm the predictive power of CD10, CD20, CD38, and CD45 as biomarkers for ALL diagnosis. Based on our analyses, we propose three increasingly detailed prognostic pipelines for analysing flow cytometry data from ALL patients depending on technical and technological availability: 1. Visual inspection of specific biological features in biparametric projections of the data; 2. Computation of quantitative topological descriptors of such projections; 3. A combined analysis, using TDA and ML, in the four-parameter space defined by CD10, CD20, CD38 and CD45. Our analyses readily extend to other haematological malignancies.
Author summary Acute lymphoblastic leukaemia (ALL) is a blood cancer which affects predominantly children and adolescents. Therapy typically fails in approximately 20 % of patients, who suffer from relapse. To determine disease status, clinicians assess cell types, their interactions, as well as deviations from normal behaviour. Flow cytometry (FC) is a method that quantifies the intensity of specific cell markers, giving rise to high-dimensional data. This routinely collected information is then reduced to obtain human-interpretable visualisation for prognosis. Topological Data Analysis (TDA) is a field of mathematics that studies shapes in data, considering isolated data islands and empty spaces between them. We showcase how to use TDA to extract shape characteristics in FC data of relapsing patients. We propose three pipelines, of increasing methodological complexity, to aid clinical decisions for risk stratification in ALL. In combination with Machine Learning, TDA enables high-accuracy predictions of relapse to be made at the time of diagnosis.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work has been partially supported by the Fundación Española para la Ciencia y la Tecnología (FECYT project PR214), the Asociación Pablo Ugarte (APU, Spain), Junta de Andalucía (Spain) group FQM-201, Junta de Comunidades de Castilla-La Mancha (grant number SBPLY/17/180501/000154), the Programme of Research and Transfer Promotion from the University of Cádiz (grant number EST2020-025), Ministery of Science and Technology, Spain (grant number PID2019-110895RB-I00, funded by MCIN/AEI/10.13039/501100011033). This work was also subsidized by a grant for the research and biomedical innovation in the health sciences within the framework of the Integrated Territorial Initiative (ITI) for the province of Cádiz (grant number ITI-0038-2019). ITI is 80% co-financed by the funds of the FEDER Operational Program of Andalusia 2014-2020 (Council of Health and Families). BJS and HMB aremembers of the Centre for Topological Data Analysis, funded by the EPSRC grant (EP/R018472/1). BJS and HMB are members of the Centre for Topological Data Analysis, funded by the EPSRC grant (EP/R018472/1).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Hospital Universitario de Jeréz de la Frontera gave ethical approval for this work. IRB of Hospital Infantil Universitario Niño Jesús gave ethical approval for this work. IRB of Hospital Universitario Vírgen del Rocío gave ethical approval for this work. IRB of Hospital Clínico Universitario Vírgen de la Arrixaca gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Introduction has been revised to reformulate the manuscript's motivation. Supplemental files have been updated. New specifications have been included in the Methods Section.
Data Availability
Implementation details, code and processed PH data are freely available on https://github.com/salvadorchulian/shapecancerrelapse. Flow cytometry files are available upon request. These datasets can be provided by the corresponding author, S.C., or H.B., pending scientific review and a completed material transfer agreement. Requests for the datasets should be submitted to: S.C., or H.B.. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials.
